I see this as their only path forward. Waiting around for reimbursement rates to get worked out through 2016-17 could bankrupt this company as they have no sales to date. It doesn't seem like they have been actively marketing this product either which leads me to believe Mgmt, is banking on a buy-out. Still the fact that this stock never held any decent gain after FDA announcement certainly disturbs me...one would think that just the speculators alone hoping for a buyout or healthy sales #'s down the road would've spiked this stock to at least $3-4 share (holding at least $2 plus). The stock market never ceases to amaze me.. just my two cents-good luck longs!